![Kripthonite logo](https://static.wixstatic.com/media/c000d6_e882faa9ca1b4c6c8cc46612bf975a19~mv2.png/v1/fill/w_280,h_91,al_c,q_85,usm_0.66_1.00_0.01,enc_auto/c000d6_e882faa9ca1b4c6c8cc46612bf975a19~mv2.png)
![](https://static.wixstatic.com/media/035244_881cbe4617f449cab844cb6a48b5fbeb~mv2_d_2475_2475_s_4_2.jpeg/v1/fill/w_562,h_562,al_c,q_80,usm_0.66_1.00_0.01,enc_auto/035244_881cbe4617f449cab844cb6a48b5fbeb~mv2_d_2475_2475_s_4_2.jpeg)
![Nomineret_Ã¥rets startup_Kripthonite Therapeutics_ENG.png](https://static.wixstatic.com/media/c000d6_814fc9d2611b4cf9b17d58f25757a1c6~mv2.png/v1/fill/w_490,h_490,al_c,q_85,usm_0.66_1.00_0.01,enc_auto/Nomineret_%C3%A5rets%20startup_Kripthonite%20Therapeutics_ENG.png)
10th of September 2024
Kripthonite Therapeutics has been nominated for Startup of the Year 2024 by Incuba!
​
We are proud of the recognition and support from Incuba. We look forward to celebrating the final winners at Aarhus Investor Summit the 3rd of October 2024 in Aarhus City Hall.
​
Incuba is the leading actor in the startup incubator scene in Jutland delivering tailored infrastructure for startups within the life science, tech and the energy sectors.
![](https://static.wixstatic.com/media/035244_881cbe4617f449cab844cb6a48b5fbeb~mv2_d_2475_2475_s_4_2.jpeg/v1/fill/w_1198,h_1198,al_c,q_85,usm_0.66_1.00_0.01,enc_auto/035244_881cbe4617f449cab844cb6a48b5fbeb~mv2_d_2475_2475_s_4_2.jpeg)
1st of May 2024
In this excellent review Sørensen and Horsman shed light on the critical issue of tumor hypoxia.* Hypoxic cancer cells, which survive in low-oxygen environments, are resistant to conventional therapies such as radiotherapy. The authors concisely summarize the changes in gene expression and metabolism as well as immunological alterations in the tumor microenvironment that arises as a result of tumor hypoxia. Furthermore, they discuss therapeutic approaches that have been tested as hypoxia-alleviating strategies.
​
According to the authors:
“In the age of targeted therapies, hypoxia has to be considered the ultimate target. Hypoxia exists in virtually all solid tumor types, it influences patient response to radio-, chemo-, and immune-therapy, and plays a major role in malignant progression.”
​
At Kripthonite Therapeutics we are rising to this challenge of targeting hypoxia with our innovative technology. Our therapy exploits the energy metabolism of hypoxic cancer cells, eradicating them in a matter of hours. This not only directly kills the cancer cells but also makes the tumor more vulnerable to conventional therapies.
​
Our lead candidate, PH1154, has shown remarkable results in preclinical studies in a hard-to-treat tumor model. Here, selective elimination of hypoxic tumor cells by PH1154 perfectly complemented the eradication of the normoxic bulk tumor by radiotherapy. This suggests the groundbreaking clinical potential of our approach.
​
Join us in our mission to save lives by eliminating hypoxic cancer cells!
​
*https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2020.00562/full
![](https://static.wixstatic.com/media/035244_881cbe4617f449cab844cb6a48b5fbeb~mv2_d_2475_2475_s_4_2.jpeg/v1/fill/w_715,h_715,al_c,q_85,usm_0.66_1.00_0.01,enc_auto/035244_881cbe4617f449cab844cb6a48b5fbeb~mv2_d_2475_2475_s_4_2.jpeg)
18th of April 2024
Exciting research published in Nature Metabolism led by Professor Leng Han (Indiana University School of Medicine) sheds light on the impact of tumor hypoxia on cancer treatment resistance. Evidently, tumor hypoxia plays a dominant role in treatment resistance and relapse of cancer.
The study reveals that patients with hypoxic tumors – irrespective of tumor type – expects a 3-year shorter survival on average compared to patients with less hypoxic tumors.* This underscores the need for a broadly applicable and effective hypoxia-targeted therapy.
​
Kripthonite’s innovative therapy holds promise for closing this survival gap by eliminating hypoxic cancer cells in solid tumors through targeting specific metabolic changes in hypoxic cancer cells.
Stay tuned for more updates on the future of hypoxia-targeted therapy in oncology!
​
![](https://static.wixstatic.com/media/035244_881cbe4617f449cab844cb6a48b5fbeb~mv2_d_2475_2475_s_4_2.jpeg/v1/fill/w_553,h_553,al_c,q_80,usm_0.66_1.00_0.01,enc_auto/035244_881cbe4617f449cab844cb6a48b5fbeb~mv2_d_2475_2475_s_4_2.jpeg)
![Erik Vinther](https://static.wixstatic.com/media/c000d6_2e1469aea61949ce947d58430bea67aa~mv2.jpg/v1/fill/w_600,h_391,al_c,q_80,usm_0.66_1.00_0.01,enc_auto/IMG_2798_JPG.jpg)
29th of November 2023
Kripthonite's CEO took the stage at the Nordic Star Pitch Competition at NLS Days 2023
![](https://static.wixstatic.com/media/035244_881cbe4617f449cab844cb6a48b5fbeb~mv2_d_2475_2475_s_4_2.jpeg/v1/fill/w_868,h_868,al_c,q_85,usm_0.66_1.00_0.01,enc_auto/035244_881cbe4617f449cab844cb6a48b5fbeb~mv2_d_2475_2475_s_4_2.jpeg)
![Nordic Star companies - NLS days 2023](https://static.wixstatic.com/media/c000d6_3414259e66e54d1faf4baf4f0ea9817d~mv2.png/v1/fill/w_660,h_593,al_c,q_90,usm_0.66_1.00_0.01,enc_auto/nordic%20star.png)
1st of November 2023
Kripthonite has been selected as a Nordic Star company at NLS Days 2023
The panelists have chosen Kripthonite as one out of 30 Nordic Star companies.
The Nordic Stars will compete in a pitch competition for the grand prize of 45,000 Euros in bioprocessing services from Merck or 10,000 Euro in cash.
![](https://static.wixstatic.com/media/035244_881cbe4617f449cab844cb6a48b5fbeb~mv2_d_2475_2475_s_4_2.jpeg/v1/fill/w_682,h_682,al_c,q_85,usm_0.66_1.00_0.01,enc_auto/035244_881cbe4617f449cab844cb6a48b5fbeb~mv2_d_2475_2475_s_4_2.jpeg)
![Kripthonite at LSX](https://static.wixstatic.com/media/c000d6_a6ff74797f6e43dcb0da9f35e32c6714~mv2.png/v1/fill/w_499,h_600,al_c,q_85,usm_0.66_1.00_0.01,enc_auto/c000d6_a6ff74797f6e43dcb0da9f35e32c6714~mv2.png)
8th-9th October 2024
Kripthonite participated in LSX Nordic 2023
We are grateful for the many positive meetings with potential investors and industry partners.